Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases analysis of a national medical claims database

Cancer

Volumn 113, Issue 6, 2008, Pages 1438-1445

  Hatounl, Hind T ^a,e   Lin, Swu Jane ^a   Smith, Mathew R ^b   Barghout, Victoria ^c   Upton, Allan ^d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^e Hind T Hatoum and Company   (United States)

Author keywords

Bone; Cancer; Persistency; Retrospective claims analysis; Skeletal complications; Zoledronic acid

Indexed keywords

ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE DISEASE; BONE METASTASIS; BREAST TUMOR; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE TUMOR; RETROSPECTIVE STUDY; SOLID TUMOR;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DATABASES, FACTUAL; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INSURANCE CLAIM REPORTING; LUNG NEOPLASMS; MALE; MEDICAL RECORDS; MIDDLE AGED; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 53149089426     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23775     Document Type: Article

References (15)

1. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(8suppl): 1588-1594.
2. Coleman RE. Management of bone metastases. Oncologist. 2000;5:463-470.
3. Delea T, Langer C, McKiernan J, et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology. 2004;67:390-396.
4. Jacobson AF, Shapiro CL, Van den Abbeele AD, Kaplan WD. Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma. Cancer. 2001;91:17-24.
5. Biermann WA, Cantor RI, Fellin FM, Jakobowski J, Hopkins L, Newbold RC III. An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone. Bone. 1991;12:S37-S42.
6. Schulman KL, Kohles J. Economic burden of metastatic bone disease in the US. Cancer. 2007; 109:2334-2342.
7. Corey E, Brown LG, Quinn JE, et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res. 2003;9:295-306.
8. Berenson JR, on behalf of the Monterey Zoledronic Acid Advisory Board. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist. 2005;10:52-62.
9. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042-4057.
10. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. j Clin Oncol. 2003;21:3150-3157.
11. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23:3314-3321.
12. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458-1468.
13. Novaris Pharmaceuticals Corporation. Zometa® (Zoledronic Acid) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2005.
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. j Chronic Dis. 1987;40:373-383.
15. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130-1139.